Novyra Pharmachem Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Rental Revenue	18.31	1.04	-	-	1.5	1.5
Total Revenue	18.01	1.04	-	-	1.5	1.5
Revenue Growth (YoY	2208.33%	-	-	-	0%	0%
Property Expenses	17.13	-	-	-	-	-
Selling, General & Administrative	0.32	0.32	0.01	0.02	-	-
Depreciation & Amortization	0.25	0.29	0.33	0.19	0.19	0.2
Other Operating Expenses	54.17	54.17	0.29	1.38	1.05	1.65
Total Operating Expenses	71.86	54.78	0.64	1.59	1.24	1.85
Operating Income	-53.86	-53.74	-0.64	-1.59	0.26	-0.35
Interest & Investment Income	-	-	-	-	0.07	0.39
Other Non-Operating Income	-0	-0	-0	-	-	0
EBT Excluding Unusual Items	-53.86	-53.74	-0.64	-1.59	0.33	0.04
Pretax Income	-53.86	-53.74	-0.64	-1.59	0.33	0.04
Income Tax Expense	-	-	-	-	0.21	0.01
Net Income	-53.86	-53.74	-0.64	-1.59	0.12	0.03
Net Income to Common	-53.86	-53.74	-0.64	-1.59	0.12	0.03
Net Income Growth	-	-	-	-	241.87%	-95.71%
Basic Shares Outstanding	6	6	6	6	6	6
Diluted Shares Outstanding	6	6	6	6	6	6
Shares Change	-21.25%	-	2.14%	-	-	-
EPS (Basic)	-8.88	-8.49	-0.10	-0.26	0.02	0.01
EPS (Diluted)	-8.88	-8.49	-0.10	-0.26	0.02	0.01
EPS Growth	-	-	-	-	241.88%	-95.71%

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Operating Margin	-299.13%	-5147.22%	-	-	17.38%	-23.57%
Profit Margin	-299.14%	-5147.32%	-	-	7.71%	2.26%
EBITDA	-53.58	-53.45	-0.3	-1.4	0.45	-0.15
EBITDA Margin	-297.59%	-	-	-	30.02%	-10.24%
D&A For Ebitda	0.28	0.29	0.33	0.19	0.19	0.2
EBIT	-53.86	-53.74	-0.64	-1.59	0.26	-0.35
EBIT Margin	-299.13%	-	-	-	17.38%	-23.57%
Effective Tax Rate	-	-	-	-	64.59%	15.61%
Revenue as Reported	18.64	1.68	0.48	-	1.57	1.89